Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

BACKGROUND: Brodalumab is efficacious for the treatment of moderate‐to‐severe plaque psoriasis through 52 weeks. OBJECTIVES: To evaluate the efficacy and safety of brodalumab through 120 weeks, including following withdrawal and retreatment. METHODS: At baseline, patients were randomized to brodalum...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, K., Menter, A., Leonardi, C., Soung, J., Weiss, S., Pillai, R., Jacobson, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754427/
https://www.ncbi.nlm.nih.gov/pubmed/32286683
http://dx.doi.org/10.1111/bjd.19132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754427/
https://www.ncbi.nlm.nih.gov/pubmed/32286683
http://dx.doi.org/10.1111/bjd.19132

Ejemplares similares